New Drugs: Antisense Agents in Cancer Research and Therapeutics
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 9 (2), 185-194
- https://doi.org/10.3109/07357909109044229
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Antisense agents in pharmacologyBiochemical Pharmacology, 1990
- G 1 /S Transition in Normal Human T-Lymphocytes Requires the Nuclear Protein Encoded by c- mybScience, 1989
- Retinoid receptor antisense DNAs inhibit alkaline phosphatase induction and clonogenicity in malignant keratinocytes.Proceedings of the National Academy of Sciences, 1989
- Antimessenger oligodeoxyribonucleotides: an alternative to antisense RNA for artificial regulation of gene expression — a reviewGene, 1988
- A c- myb Antisense Oligodeoxynucleotide Inhibits Normal Human Hematopoiesis in VitroScience, 1988
- An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation.Molecular and Cellular Biology, 1988
- Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.Proceedings of the National Academy of Sciences, 1988
- Oligonucleotide Analogues as Potential Chemotherapeutic AgentsPharmaceutical Research, 1988
- A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1Nature, 1987
- Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.Proceedings of the National Academy of Sciences, 1978